Replivir
Generic Name
Dolutegravir
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| replivir 1 mg tablet | ৳ 90.00 | ৳ 900.00 |
| replivir 05 mg tablet | ৳ 50.00 | ৳ 500.00 |
Description
Overview of the medicine
Replivir (Dolutegravir) is an antiretroviral medication used for the treatment of HIV-1 infection in adults and adolescents. It belongs to a class of drugs called integrase strand transfer inhibitors (INSTIs).
Uses & Indications
Dosage
Adults
50 mg once daily, taken orally with or without food.
Elderly
No specific dosage adjustment is required for elderly patients.
Renal_impairment
No dosage adjustment needed for mild to moderate renal impairment. For severe impairment or end-stage renal disease, consult a physician.
How to Take
Take orally with or without food. It can be taken at any time of day.
Mechanism of Action
Dolutegravir inhibits HIV integrase, an enzyme necessary for HIV replication. By blocking the integrase enzyme, it prevents HIV DNA from integrating into the host cell genome, thereby stopping the viral replication cycle.
Pharmacokinetics
Onset
Rapid onset of antiviral effect, typically within hours of first dose.
Excretion
Approximately 53% excreted unchanged in feces and 32% as metabolites in urine.
Half life
Approximately 14 hours
Absorption
Rapidly absorbed after oral administration. Tmax is typically 2-3 hours post-dose.
Metabolism
Primarily metabolized by UGT1A1, with some contribution from CYP3A.
Side Effects
Contraindications
- Hypersensitivity to dolutegravir or any component of the formulation
- Co-administration with dofetilide
Drug Interactions
Metformin
Dolutegravir increases metformin concentrations; dose adjustment of metformin may be necessary.
Dofetilide
Co-administration is contraindicated due to increased dofetilide plasma concentrations and risk of severe adverse events.
Antacids/Cation-containing laxatives
Should be taken at least 2 hours before or 6 hours after dolutegravir.
Storage
Store below 30°C in a dry place, away from direct sunlight and moisture. Keep out of reach of children.
Overdose
Limited experience with overdose. Management should involve general supportive measures, including monitoring of vital signs and observation of the patient's clinical status.
Pregnancy & Lactation
Pregnancy Category B/C. Data from surveillance studies indicate no increased risk of neural tube defects when initiated in the second or third trimester. However, caution is advised if initiated at conception. Consult a physician for use during pregnancy and lactation.
Side Effects
Contraindications
- Hypersensitivity to dolutegravir or any component of the formulation
- Co-administration with dofetilide
Drug Interactions
Metformin
Dolutegravir increases metformin concentrations; dose adjustment of metformin may be necessary.
Dofetilide
Co-administration is contraindicated due to increased dofetilide plasma concentrations and risk of severe adverse events.
Antacids/Cation-containing laxatives
Should be taken at least 2 hours before or 6 hours after dolutegravir.
Storage
Store below 30°C in a dry place, away from direct sunlight and moisture. Keep out of reach of children.
Overdose
Limited experience with overdose. Management should involve general supportive measures, including monitoring of vital signs and observation of the patient's clinical status.
Pregnancy & Lactation
Pregnancy Category B/C. Data from surveillance studies indicate no increased risk of neural tube defects when initiated in the second or third trimester. However, caution is advised if initiated at conception. Consult a physician for use during pregnancy and lactation.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months
Availability
Available in pharmacies and hospitals
Approval Status
Approved by FDA (USA) and DGDA (Bangladesh)
Patent Status
Patent protected, with generic versions available through voluntary licensing in many developing countries
WHO Essential Medicine
YesClinical Trials
Dolutegravir has been extensively studied in numerous pivotal clinical trials (e.g., SPRING-1, SPRING-2, SINGLE, FLAMINGO) demonstrating its efficacy and safety in various patient populations, including treatment-naive and treatment-experienced individuals.
Lab Monitoring
- HIV viral load
- CD4 cell count
- Liver function tests (ALT, AST, bilirubin)
- Renal function (creatinine)
Doctor Notes
- Emphasize strict adherence to therapy to prevent resistance development.
- Educate patients on potential adverse effects, especially hypersensitivity reactions and liver toxicity.
- Regular monitoring of renal and liver function is recommended.
Patient Guidelines
- Take consistently every day at the same time
- Do not stop taking the medicine without consulting your doctor
- Report any new or worsening symptoms to your healthcare provider
Missed Dose Advice
If a dose is missed, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take your next dose at the regular time. Do not take a double dose to make up for a missed one.
Driving Precautions
Dolutegravir may cause dizziness or fatigue. Patients should be advised to exercise caution when driving or operating machinery until they know how the medication affects them.
Lifestyle Advice
- Maintain a healthy diet and regular exercise routine
- Practice safe sex to prevent transmission of HIV
- Avoid alcohol and illicit drugs that can harm the liver
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Replivir Brand
Other medicines available under the same brand name
